These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28600556)

  • 1. Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.
    Sonowal H; Pal PB; Wen JJ; Awasthi S; Ramana KV; Srivastava SK
    Sci Rep; 2017 Jun; 7(1):3182. PubMed ID: 28600556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.
    Sonowal H; Pal P; Shukla K; Saxena A; Srivastava SK; Ramana KV
    Biochem Pharmacol; 2018 Apr; 150():181-190. PubMed ID: 29458045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells.
    Shukla K; Sonowal H; Saxena A; Ramana KV; Srivastava SK
    Cancer Lett; 2017 Dec; 411():57-63. PubMed ID: 28986187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
    Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
    Saxena A; Shoeb M; Ramana KV; Srivastava SK
    Eur J Cancer; 2013 Oct; 49(15):3311-9. PubMed ID: 23827854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis.
    Sonowal H; Saxena A; Qiu S; Srivastava S; Ramana KV
    Eur J Pharmacol; 2021 Mar; 895():173884. PubMed ID: 33482179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
    Ramana KV; Tammali R; Srivastava SK
    Mol Cancer Ther; 2010 Apr; 9(4):813-24. PubMed ID: 20354121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
    Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
    BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
    Tammali R; Ramana KV; Singhal SS; Awasthi S; Srivastava SK
    Cancer Res; 2006 Oct; 66(19):9705-13. PubMed ID: 17018629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
    Marklein D; Graab U; Naumann I; Yan T; Ridzewski R; Nitzki F; Rosenberger A; Dittmann K; Wienands J; Wojnowski L; Fulda S; Hahn H
    PLoS One; 2012; 7(12):e52898. PubMed ID: 23300809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study.
    Pandey S
    Asian Pac J Cancer Prev; 2015; 16(12):4981-5. PubMed ID: 26163626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity.
    Lucas A; Lam D; Cabrales P
    Drug Deliv; 2019 Dec; 26(1):433-442. PubMed ID: 30929538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.
    Argov M; Kashi R; Peer D; Margalit R
    Cancer Lett; 2009 Feb; 274(1):118-25. PubMed ID: 18851896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in Apc
    Saxena A; Tammali R; Ramana KV; Srivastava SK
    Curr Cancer Drug Targets; 2018; 18(9):905-911. PubMed ID: 28786349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of aldose reductase prevents colon cancer metastasis.
    Tammali R; Reddy AB; Saxena A; Rychahou PG; Evers BM; Qiu S; Awasthi S; Ramana KV; Srivastava SK
    Carcinogenesis; 2011 Aug; 32(8):1259-67. PubMed ID: 21642355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
    Yan X; Zhao J; Zhang R
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres.
    Laurand A; Laroche-Clary A; Larrue A; Huet S; Soma E; Bonnet J; Robert J
    Anticancer Res; 2004; 24(6):3781-8. PubMed ID: 15736412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.